Information

Related Research Units

Gastroenterology, Hepatology and Nutrition Research

Research Overview

Dr. Bousvaros studies the pathogenesis and therapy of inflammatory bowel disease (IBD). Goals of Dr. Bousvaros's research include the identification of microbial pathogens that may trigger exacerbations of Crohn's disease or ulcerative colitis and the evaluation of probiotic therapies in the treatment of IBD. 

Research Background

Dr. Bousvaros received an MD from Duke University and an MPH from the Harvard School of Public Health. He completed fellowships at Children's Hospital Boston and Massachusetts General Hospital.

Education

Medical School

Duke University School of Medicine
1985 Durham NC

Internship

Duke University Hospital
1986 Durham NC

Residency

Duke University Hospital
1988 Durham NC

Fellowship

Boston Children's Hospital
1991 Boston MA

Fellowship

Clinical Research/Pediatric Gastroenterology and Nutrition Boston Combined Residency Program (BCRP)
1991 Boston MA

Media

Caregiver Profile

Meet Dr. Athos Bousvaros

Publications

  1. Incidence, risk factors, and treatment patterns of pouchitis in pediatric ulcerative colitis. Inflamm Bowel Dis. 2026 Sep 26. View Abstract
  2. GPR15-guided CD8+ T regulatory cells control intestinal inflammation. Nature. 2026 Aug; 656(8129):1003-1012. View Abstract
  3. Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2026 02; 11(2):100-109. View Abstract
  4. Antimicrobial susceptibility-guided treatment is superior to empiric therapy for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2025 Nov; 81(5):1133-1141. View Abstract
  5. Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease. Inflamm Bowel Dis. 2025 Jul 07; 31(7):1841-1850. View Abstract
  6. Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025 Jul 07; 31(7):1797-1805. View Abstract
  7. Clinical outcomes of maintenance therapy with sulfasalazine compared to 5-aminosalicylates in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2025 06; 80(6):988-997. View Abstract
  8. HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. Am J Gastroenterol. 2024 Oct 18. View Abstract
  9. HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. Am J Gastroenterol. 2025 May 01; 120(5):1076-1086. View Abstract
  10. Cytomegalovirus Colitis in a Patient With Ulcerative Colitis With Loss of Corticosteroid Response Upon Upadacitinib Initiation. Gastroenterol Hepatol (N Y). 2024 Oct; 20(9):546-549. View Abstract
  11. Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 09 03; 30(9):1443-1453. View Abstract
  12. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after fecal microbiota transplant in inflammatory bowel disease. Sci Rep. 2024 08 06; 14(1):18188. View Abstract
  13. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease. Am J Gastroenterol. 2024 06 01; 119(6):1110-1116. View Abstract
  14. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024 Jul; 22(7):1475-1486.e4. View Abstract
  15. Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024 04; 78(4):871-877. View Abstract
  16. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024 02; 78(2):261-271. View Abstract
  17. Collaborative Registries for Pediatric Crohn's Disease: A Leap Forward or More of the Same? Am J Gastroenterol. 2024 03 01; 119(3):450-451. View Abstract
  18. Comparing Gastrointestinal Endoscopy Findings in Children with Autism, Developmental Delay, or Typical Development. J Pediatr. 2024 01; 264:113737. View Abstract
  19. Endoscopy of the Ileal Pouch Anal Anastomosis. J Pediatr Gastroenterol Nutr. 2023 12 01; 77(6):691-694. View Abstract
  20. Reply. Gastroenterology. 2023 Nov; 165(5):1308. View Abstract
  21. Helicobacter pylori Antimicrobial Resistance Using Next-Generation Sequencing in Stool Samples in a Pediatric Population. J Pediatr Gastroenterol Nutr. 2023 11 01; 77(5):623-627. View Abstract
  22. Treatment of Genital Crohn's Disease With Upadacitinib in a Male Child: A Case Report. Gastroenterol Hepatol (N Y). 2023 Jul; 19(7):401-403. View Abstract
  23. Efficacy and Safety of Tacrolimus or Infliximab Therapy in Children and Young Adults With Acute Severe Colitis. J Pediatr Gastroenterol Nutr. 2023 08 01; 77(2):222-227. View Abstract
  24. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial. Gastroenterology. 2023 07; 165(1):149-161.e7. View Abstract
  25. Helicobacter pylori Antimicrobial Resistance in a Pediatric Population From the New England Region of the United States. Clin Gastroenterol Hepatol. 2023 12; 21(13):3458-3460.e2. View Abstract
  26. Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 03 01; 29(3):483-486. View Abstract
  27. How to Write an Effective Letter of Medical Necessity. J Pediatr Gastroenterol Nutr. 2023 04 01; 76(4):407-409. View Abstract
  28. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after Fecal Microbiota Transplant in Inflammatory Bowel Disease. medRxiv. 2023 Feb 01. View Abstract
  29. Efficacy and Safety of Sulfasalazine Suspension in Children With Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2023 04 01; 76(4):460-467. View Abstract
  30. Development and Validation of the TUMMY-UC: A Patient-Reported Outcome for Pediatric Ulcerative Colitis. Gastroenterology. 2023 04; 164(4):610-618.e4. View Abstract
  31. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Inflamm Bowel Dis. 2022 10 03; 28(10):1497-1505. View Abstract
  32. Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease. Am J Gastroenterol. 2023 01 01; 118(1):129-137. View Abstract
  33. Clinical Phenotypes and Outcomes in Monogenic Versus Non-monogenic Very Early Onset Inflammatory Bowel Disease. J Crohns Colitis. 2022 Sep 08; 16(9):1380-1396. View Abstract
  34. Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr. 2022 10 01; 75(4):418-422. View Abstract
  35. Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2022 03 01; 117(3):462-469. View Abstract
  36. Lessons From a Quality Improvement Project to Standardize the Process of Gastric Biopsy Culture for Helicobacter pylori. JPGN Rep. 2021 Nov; 2(4):e116. View Abstract
  37. Agreement on Symptoms Between Children With Ulcerative Colitis and Their Caregivers: Towards Developing the TUMMY-UC. J Pediatr Gastroenterol Nutr. 2021 08 01; 73(2):e35-e38. View Abstract
  38. Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease. Gastroenterology. 2020 08; 159(2):591-608.e10. View Abstract
  39. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis. 2020 05 12; 26(6):820-842. View Abstract
  40. The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease. Gastroenterol Rep (Oxf). 2020 Oct; 8(5):404-406. View Abstract
  41. Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn's Disease Cohort. Inflamm Bowel Dis. 2019 11 14; 25(12):1927-1938. View Abstract
  42. Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease. PLoS One. 2019; 14(10):e0222952. View Abstract
  43. The pharmacotherapeutic management of pediatric Crohn's disease. Expert Opin Pharmacother. 2019 Dec; 20(17):2161-2168. View Abstract
  44. Natural history of children with mild Crohn's disease. World J Gastroenterol. 2019 08 14; 25(30):4235-4245. View Abstract
  45. Commentary: Monitoring Thiopurine Efficacy Without Levels: Is It a Good Idea? J Pediatr Gastroenterol Nutr. 2019 07; 69(1):1-2. View Abstract
  46. Microscopic/"Backwash" Ileitis and Its Association With Colonic Disease in New Onset Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2019 06; 68(6):835-840. View Abstract
  47. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019 05 16; 25(Suppl 2):S40-S47. View Abstract
  48. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut. 2020 01; 69(1):32-41. View Abstract
  49. Microscopic / "Backwash" Ileitis and its Association with Colonic Disease in New Onset Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2019 Jan 21. View Abstract
  50. Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBD. Inflamm Bowel Dis. 2019 01 01; 25(1):27-32. View Abstract
  51. Reducing Redundant Anaerobic Therapy Through Spaced Education and Antimicrobial Stewardship Interventions. J Pediatric Infect Dis Soc. 2018 Dec 03; 7(4):317-322. View Abstract
  52. Mucosal Gene Expression in Pediatric and Adult Patients With Ulcerative Colitis Permits Modeling of Ideal Biopsy Collection Strategy for Transcriptomic Analysis. Inflamm Bowel Dis. 2018 11 29; 24(12):2565-2578. View Abstract
  53. Curved planar reformatting and convolutional neural network-based segmentation of the small bowel for visualization and quantitative assessment of pediatric Crohn's disease from MRI. J Magn Reson Imaging. 2019 06; 49(6):1565-1576. View Abstract
  54. The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 05 18; 24(6):1344-1351. View Abstract
  55. Educational needs in the diagnosis and management of pediatric functional constipation: a US survey of specialist and primary care clinicians. Postgrad Med. 2018 May; 130(4):428-435. View Abstract
  56. Commentary: Button Batteries in Fidget Spinners: Is It Time to Push the "Panic Button"? J Pediatr Gastroenterol Nutr. 2018 04; 66(4):557-558. View Abstract
  57. Biologics Delay Progression of Crohn's Disease, but Not Early Surgery, in Children. Clin Gastroenterol Hepatol. 2018 09; 16(9):1467-1473. View Abstract
  58. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. Gut. 2019 02; 68(2):239-247. View Abstract
  59. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab. J Pediatr Surg. 2018 Jul; 53(7):1330-1333. View Abstract
  60. Enhanced TH17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD. Inflamm Bowel Dis. 2017 11; 23(11):1950-1961. View Abstract
  61. Human RELA haploinsufficiency results in autosomal-dominant chronic mucocutaneous ulceration. J Exp Med. 2017 Jul 03; 214(7):1937-1947. View Abstract
  62. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol. 2017 May 14; 23(18):3322-3329. View Abstract
  63. Outcomes From Pediatric Gastroenterology Maintenance of Certification Using Web-based Modules. J Pediatr Gastroenterol Nutr. 2017 05; 64(5):671-678. View Abstract
  64. From "Jarts" to "Zen Magnets": Protecting Our Children from Dangerous Toys. J Pediatr. 2017 07; 186:6-7. View Abstract
  65. O-011 Low-dose IL-2 Administration Expands Human Regulatory T Cells in Patients with UC and Humanized Mice and Protects Against Experimental Colitis. Inflamm Bowel Dis. 2017 Feb; 23 Suppl 1:S4. View Abstract
  66. Effect of Psychotherapy on Health Care Utilization in Children With Inflammatory Bowel Disease and Depression. J Pediatr Gastroenterol Nutr. 2016 12; 63(6):658-664. View Abstract
  67. Interleukin 1ß Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency. Gastroenterology. 2016 12; 151(6):1100-1104. View Abstract
  68. Postoperative Complications in Children With Crohn Disease Treated With Infliximab. J Pediatr Gastroenterol Nutr. 2016 09; 63(3):352-6. View Abstract
  69. Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents. J Pediatr. 2016 Nov; 178:227-232. View Abstract
  70. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-a Inhibitors. J Pediatr Gastroenterol Nutr. 2016 07; 63(1):130-55. View Abstract
  71. O-017 YI Inflammatory Versus Non-inflammatory Predictors of Specific Depressive Symptoms in a Large Pediatric Cohort with IBD. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S6. View Abstract
  72. Prevalence of Inflammatory Bowel Disease Among Patients with Autism Spectrum Disorders. Inflamm Bowel Dis. 2015 Oct; 21(10):2281-8. View Abstract
  73. Thalidomide Treatment of Pediatric Ulcerative Colitis: A New Use for an Old Drug. Inflamm Bowel Dis. 2015 Aug; 21(8):1750-1. View Abstract
  74. Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1321-8. View Abstract
  75. Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. J Pediatr. 2015 Sep; 167(3):527-32.e1-3. View Abstract
  76. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1748-56. View Abstract
  77. Surgical management and morbidity of pediatric magnet ingestions. J Surg Res. 2015 Nov; 199(1):137-40. View Abstract
  78. Villin immunohistochemistry is a reliable method for diagnosing microvillus inclusion disease. Am J Surg Pathol. 2015 Feb; 39(2):245-50. View Abstract
  79. Functional significance of single nucleotide polymorphisms in the lactase gene in diverse US patients and evidence for a novel lactase persistence allele at -13909 in those of European ancestry. J Pediatr Gastroenterol Nutr. 2015 Feb; 60(2):182-91. View Abstract
  80. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm Bowel Dis. 2015 Feb; 21(2):307-14. View Abstract
  81. Efficacy of oral methotrexate in paediatric Crohn's disease: a multicentre propensity score study. Gut. 2015 Dec; 64(12):1898-904. View Abstract
  82. Predictors of abdominal pain in depressed pediatric inflammatory bowel disease patients. Inflamm Bowel Dis. 2014 Aug; 20(8):1329-40. View Abstract
  83. Benefit/risk assessment of biologic monotherapy vs combination therapy in Crohn's Remains Challenging. Gastroenterology. 2014 Aug; 147(2):540. View Abstract
  84. Pediatric ulcerative colitis: a practical guide to management. Paediatr Drugs. 2014 Jun; 16(3):189-98. View Abstract
  85. The effect of immunomodulators and biologics on indication for surgical bowel resection in children with Crohn's disease. Inflamm Bowel Dis. 2014 Jun; 20(6):1015-20. View Abstract
  86. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y). 2014 Jun; 10(6):355-63. View Abstract
  87. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry. 2014 Jul; 53(7):726-35. View Abstract
  88. Authors' response. J Pediatr Gastroenterol Nutr. 2014 May; 58(5):e51. View Abstract
  89. Predictors of depression in youth with Crohn disease. J Pediatr Gastroenterol Nutr. 2014 May; 58(5):569-73. View Abstract
  90. Depression subtypes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2014 May; 58(5):574-81. View Abstract
  91. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. BMC Gastroenterol. 2014 Apr 09; 14:71. View Abstract
  92. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb; 58(3):309-18. View Abstract
  93. Advocating for child health: how the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition took action against high-powered magnets. J Pediatr. 2014 Jan; 164(1):4-5.e1. View Abstract
  94. NASPGHAN single-topic symposium: discovering the future of pediatric IBD care. J Pediatr Gastroenterol Nutr. 2014 Jan; 58(1):130-8. View Abstract
  95. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb; 58(3):e44-100. View Abstract
  96. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013 Sep; 57(3):343-7. View Abstract
  97. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013 Sep; 57(3):293-7. View Abstract
  98. Characterization of relations among sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn disease. J Pediatr Gastroenterol Nutr. 2013 Sep; 57(3):335-42. View Abstract
  99. Predictive value of the Pediatric Ulcerative Colitis Activity Index in the surgical management of ulcerative colitis. J Pediatr Surg. 2013 Jul; 48(7):1540-5. View Abstract
  100. Characterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease. PLoS One. 2013; 8(6):e63686. View Abstract
  101. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jun; 19(7):1441-9. View Abstract
  102. The overlap of functional abdominal pain in pediatric Crohn's disease. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):826-31. View Abstract
  103. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum. Expert Rev Clin Immunol. 2013 Feb; 9(2):117-27. View Abstract
  104. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013 Jan; 56(1):12-8. View Abstract
  105. Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease. J Int Neuropsychol Soc. 2013 Jan; 19(1):96-109. View Abstract
  106. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr. 2012 Sep; 55(3):239-42. View Abstract
  107. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. J Clin Psychol Med Settings. 2012 Sep; 19(3):329-37. View Abstract
  108. Characterization of fast and slow diffusion from diffusion-weighted MRI of pediatric Crohn's disease. J Magn Reson Imaging. 2013 Jan; 37(1):156-63. View Abstract
  109. Budesonide use in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012 Aug; 55(2):200-4. View Abstract
  110. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012 Sep; 107(9):1399-406. View Abstract
  111. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One. 2012; 7(6):e39242. View Abstract
  112. An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc. 2013 Jan 01; 20(1):172-9. View Abstract
  113. Using the Children's Depression Inventory in youth with inflammatory bowel disease: support for a physical illness-related factor. Compr Psychiatry. 2012 Nov; 53(8):1194-9. View Abstract
  114. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012 Apr 16; 13(9):R79. View Abstract
  115. Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012 May; 18(5):935-42. View Abstract
  116. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis. 2012 May; 18(5):838-43. View Abstract
  117. "Tac"kling a difficult problem: using tacrolimus to maintain remission in ulcerative colitis. J Clin Gastroenterol. 2011 Jul; 45(6):479-80. View Abstract
  118. Agreement between patient- and physician-completed Pediatric Ulcerative Colitis Activity Index scores. J Pediatr Gastroenterol Nutr. 2011 Jun; 52(6):708-13. View Abstract
  119. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011 Apr; 106(4):574-88. View Abstract
  120. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011 May; 106(5):981-7. View Abstract
  121. Innate and adaptive immune connections in inflammatory bowel diseases. Curr Opin Gastroenterol. 2010 Nov; 26(6):572-7. View Abstract
  122. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011 Jan; 17(1):22-9. View Abstract
  123. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010 Aug; 51(2):140-5. View Abstract
  124. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul; 6(4):659-66. View Abstract
  125. Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol. 2010 Sep; 8(9):789-94. View Abstract
  126. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr. 2010 May; 50(5):562-5. View Abstract
  127. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010 Jun; 105(6):1430-6. View Abstract
  128. Probiotic for new onset ulcerative colitis in children: baby's got bac(teria). Inflamm Bowel Dis. 2010 Jan; 16(1):177-8. View Abstract
  129. Monitoring Disease Activity in Pediatric IBD Patients (monograph). Children's Digestive Health and Nutrition Foundation 2009 . 2010. View Abstract
  130. Healthcare burden of inflammatory bowel disease in the United States: more than pain and diarrhea. Inflamm Bowel Dis. 2009 Nov; 15(11):1767-8. View Abstract
  131. Restorative proctocolectomy and ileal pouch-anal anastomosis in children. Dis Colon Rectum. 2009 Sep; 52(9):1645-9. View Abstract
  132. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009 Sep; 15(9):1417-23. View Abstract
  133. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2009 Sep; 49(3):297-303. View Abstract
  134. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009 Aug; 15(8):1218-23. View Abstract
  135. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009 Jun; 15(6):816-22. View Abstract
  136. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. Inflamm Bowel Dis. 2009 Mar; 15(3):383-7. View Abstract
  137. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009 Feb; 48(2):168-74. View Abstract
  138. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009 Feb; 104(2):444-53. View Abstract
  139. Making the right diagnosis: differentiating between Crohn disease and ulcerative colitis in children and young adults. . 2009. View Abstract
  140. Approach to clinical diagnosis of inflammatory bowel disease. In: Walker-Smith JA, Lebenthal E, Branski D. Pediatric Inflammatory Bowel Disease: Perspective and consequences. 2009; 123-137. View Abstract
  141. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res. 2008 Aug; 52(8):867-74. View Abstract
  142. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. 2008 Jul; 14(7):949-54. View Abstract
  143. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008 Apr; 20(4):269-84. View Abstract
  144. Research and clinical challenges in paediatric inflammatory bowel disease. Dig Liver Dis. 2008 Jan; 40(1):32-8. View Abstract
  145. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry. 2007 Oct; 46(10):1290-1298. View Abstract
  146. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007 Dec; 5(12):1424-9. View Abstract
  147. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr. 2007 Nov; 151(5):523-7. View Abstract
  148. Challenges and progress in pediatric inflammatory bowel disease. Curr Opin Gastroenterol. 2007 Jul; 23(4):406-12. View Abstract
  149. Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis. 2007 Jul; 13(7):890-5. View Abstract
  150. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007 Jun; 119(6):1113-9. View Abstract
  151. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007 May; 44(5):653-74. View Abstract
  152. Pete Learns About Crohn's and Colitis. 2007. View Abstract
  153. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J Pediatr Surg. 2007 Jan; 42(1):31-4; discussion 34-5. View Abstract
  154. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006 Dec; 12(12):1101-6. View Abstract
  155. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006 Sep; 12(9):885-913. View Abstract
  156. Health-related quality of life in the first year after a diagnosis of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006 Aug; 12(8):684-91. View Abstract
  157. Effective advocacy for patients with inflammatory bowel disease: communication with insurance companies, school administrators, employers, and other health care overseers. Inflamm Bowel Dis. 2006 Aug; 12(8):814-23. View Abstract
  158. Medical therapy for refractory pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2006 Oct; 4(10):1199-213. View Abstract
  159. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006 Sep; 4(9):1124-9. View Abstract
  160. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006 Sep; 4(9):1118-23. View Abstract
  161. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006 Apr; 12(4):251-7. View Abstract
  162. Gastrointestinal issues in developmentally disabled children. LI Rubin and AC Crocker eds. Medical Care for children and adults with developmental disabilities. 2006; 307-324. View Abstract
  163. Current therapy of inflammatory bowel disease in children. Paediatr Drugs. 2006; 8(5):279-302. View Abstract
  164. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005 Oct; 41(4):416-21. View Abstract
  165. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005 Sep; 11(9):833-9. View Abstract
  166. Workshop report: prevention of postoperative recurrence in Crohn's disease. J Pediatr Gastroenterol Nutr. 2005 Aug; 41(2):145-51. View Abstract
  167. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm Bowel Dis. 2005 Jun; 11(6):519-27. View Abstract
  168. Normal homocysteine levels in a population of children with inflammatory bowel disease. Inflamm Bowel Dis. 2005 Jun; 11(6):620-1. View Abstract
  169. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis. 2005 Feb; 11(2):185-96. View Abstract
  170. Probiotic Therapies: the crossroads of traditional and alternative medicine. Practical Gastroenterology. 2005; 4:20-36. View Abstract
  171. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004 Nov; 99(11):2235-41. View Abstract
  172. Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr. 2004 Oct; 39(4):395-403. View Abstract
  173. Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill? Inflamm Bowel Dis. 2004 Jul; 10(4):481-3. View Abstract
  174. Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. Am J Surg Pathol. 2004 Feb; 28(2):190-7. View Abstract
  175. Gastroenterology questions for the American Academy of Pediatrics PREP course. Available on www.pedialink.org. 2004. View Abstract
  176. Immunosuppressive therapies. Walker WA, Goulet O, Kleinman R, Sherman P, Shneider B, Sanderson I eds. Pediatric Gastrointestinal Disease. 2004; 2:2015-2044. View Abstract
  177. Pediatric Crohn's disease. Johnson L ed. Encyclopedia of Gastroenterology. 2004; 520-527. View Abstract
  178. Ulcerative colitis. Guandalini ed, Textbook of Pediatric Gastroenterology. 2004; 385-418. View Abstract
  179. Gastroenterologic and Liver Disorders. Stiehm ER, Ochs H, Winkelstein J eds. Immunologic disorders in infants and children. 2004; 1055-1102. View Abstract
  180. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003 Dec; 98(12):2712-8. View Abstract
  181. Blocking lymphocyte adhesion: new treatment for sticky cases of Crohn disease? J Pediatr Gastroenterol Nutr. 2003 Aug; 37(2):211-3. View Abstract
  182. Isolated neonatal swallowing dysfunction: a case series and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):30-5. View Abstract
  183. Nutritional therapy of inflammatory bowel disease. Caballero B, Trugo L, Finglas P eds. Encyclopedia of Food Sciences and Nutrition. 2003; 3315-3320. View Abstract
  184. Webcast: Crohn's and colitis Foundation - Management of IBD in special populations. Available on www.ccfa.org. 2003. View Abstract
  185. Feeding tubes. Puder M, Hansen A eds. Manual of Neonatal Surgical Care. 2003; 303-314. View Abstract
  186. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002 Nov; 47(11):2625-34. View Abstract
  187. Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2002 Nov; 35(5):695-9. View Abstract
  188. Blame Canada: growing questions about budesonide. Inflamm Bowel Dis. 2002 May; 8(3):235. View Abstract
  189. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol. 2002 Feb; 97(2):382-8. View Abstract
  190. Research agenda for pediatric gastroenterology, hepatology and nutrition: chronic inflammatory bowel disease. Report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for the Children's Digestive Health and Nutrition Foundation. J Pediatr Gastroenterol Nutr. 2002; 35 Suppl 3:S286-90. View Abstract
  191. Board review questions in pediatric gastroenterology for the American Academy of Pediatrics PREP the course. 16 Questions per year for 6 years (2002-2008). 2002. View Abstract
  192. Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001 Nov; 33(5):548-53. View Abstract
  193. Inflammatory bowel disease associated with immune thrombocytopenic purpura in children. J Pediatr Gastroenterol Nutr. 2001 Nov; 33(5):582-7. View Abstract
  194. Multiple micronutrient deficiencies in a child fed an elemental formula. J Pediatr Gastroenterol Nutr. 2001 Nov; 33(5):602-5. View Abstract
  195. Abdominal migraine in children with neurofibromatosis type 1: a case series and review of gastrointestinal involvement in NF1. J Pediatr Gastroenterol Nutr. 2001 Aug; 33(2):149-54. View Abstract
  196. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001 Jan; 120(1):13-20. View Abstract
  197. Thalidomide in gastrointestinal disorders. Drugs. 2001; 61(6):777-87. View Abstract
  198. Epidemiology and diagnosis of inflammatory bowel disease. Bonis ed., Up to Date. 2001; 9. View Abstract
  199. The spectrum of pediatric gastroesophageal reflux. JAMA. 2000 Dec 27; 284(24):3125-6. View Abstract
  200. Oral tacrolimus treatment of severe colitis in children. J Pediatr. 2000 Dec; 137(6):794-9. View Abstract
  201. Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children. Dig Dis Sci. 1999 Dec; 44(12):2500-7. View Abstract
  202. Allergic esophagitis in children: a clinicopathological entity. Am J Surg Pathol. 1999 Apr; 23(4):390-6. View Abstract
  203. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci. 1999 Feb; 44(2):424-30. View Abstract
  204. Gastrointestinal Manifestations of Primary Immunodeficiencies. Wyllie R, Hyams JS. Pediatric Gastrointestinal Disease. 1999; 381-389. View Abstract
  205. Crohn's disease in children and adolescents. Bonis ed, Up to Date (CD-ROM). 1999; 8. View Abstract
  206. Ulcerative Colitis in children and adolescents. Bonis ed, Up to Date (CD-ROM). 1999. View Abstract
  207. Gastrointestinal issues in the child with developmental disabilities. International Seminars in Pediatric Gastroenterology and Nutrition. 1999; 8:1-9. View Abstract
  208. Intraduodenal hematoma complicating intestinal biopsy: case reports and review of the literature. Am J Gastroenterol. 1998 Dec; 93(12):2547-50. View Abstract
  209. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med. 1998 Nov; 152(11):1132-6. View Abstract
  210. Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis. Pediatr Pulmonol. 1998 Nov; 26(5):365-9. View Abstract
  211. Serum leptin in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998 May; 26(5):500-5. View Abstract
  212. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr. 1998 Feb; 26(2):129-35. View Abstract
  213. Clinical outcome of ulcerative proctitis in children. J Pediatr Gastroenterol Nutr. 1997 Aug; 25(2):149-52. View Abstract
  214. Preventing relapse after surgery for Crohn's disease: where do we go from here? J Pediatr Gastroenterol Nutr. 1997 Jul; 25(1):114-5. View Abstract
  215. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes. Dig Dis Sci. 1997 Jul; 42(7):1542-8. View Abstract
  216. Serum basic fibroblast growth factor in pediatric Crohn's disease. Implications for wound healing. Dig Dis Sci. 1997 Feb; 42(2):378-86. View Abstract
  217. Gastroenterologic Disorders. Graef J, Priebe C eds. Manual of Pediatric Therapeutics. 1997. View Abstract
  218. Immunosuppressive Agents in Gastrointestinal Disease. Kresina T, ed. Manual of Immune Modulating Agents. 1997. View Abstract
  219. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr. 1996 Oct; 23(3):329-33. View Abstract
  220. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J Pediatr Gastroenterol Nutr. 1996 Aug; 23(2):164-71. View Abstract
  221. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology. 1996 Jul; 111(1):237-43. View Abstract
  222. Immunology and Gastrointestinal Disease. Stiehm ER ed, Immunologic Disorders of Infants and Children. 1995; 697-741. View Abstract
  223. Immunosuppressive Agents in Gastrointestinal Disease. Current Opinion in Gastroenterology. 1995; 11:554-561. View Abstract
  224. Immunosuppressive therapies in Pediatric Gastroenterology. Walker WA, Hamilton JR, Watkins JB, Walker-Smith JA, Durie PR. Pediatric Gastrointestinal Disease. 1995. View Abstract
  225. New immunotherapies and their potential for treatment of inflammatory bowel disease. Progress in Inflammatory Bowel Disease. 1993; 14:6-11. View Abstract
  226. Immunology and Gastrointestinal Disease. Wyllie R and Hyams J eds., Pediatric Gastrointestinal Disease. 1993; 64-73. View Abstract
  227. Basic gastrointestinal immunology. Bouchier IA, Hodgson HJ, Keighley MR eds., Gastroenterology: Clinical Science and Practice. 1993; 577-582. View Abstract
  228. Ringed esophagus: an association with esophagitis. Am J Gastroenterol. 1992 Sep; 87(9):1187-90. View Abstract
  229. Development of the Intestinal Mucosal Barrier. McDonald TT ed, Ontogeny of the Immune System of the Gut. 1991. View Abstract
  230. Diarrhea in the Immunodeficient Host. Rudolph's Textbook of Pediatrics. 1991; 1012-1015. View Abstract
  231. Abdominal Wall Defects. Rudolph Textbook of Pediatrics. 1991; 1040-1042. View Abstract
  232. Imaging of neuroblastoma: an overview. Pediatr Radiol. 1986; 16(2):89-106. View Abstract
  233. Monoclonal antibody phenotyping of B-cell non-Hodgkin's lymphomas. The Southeastern Cancer Study Group experience. Am J Pathol. 1985 Dec; 121(3):514-21. View Abstract

Contact Athos Bousvaros

Print Profile